12 Pharmaceuticals Stocks to Sell Now

12 Pharmaceuticals Stocks to Sell Now

This week, the overall grades of 12 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA) declines this week from a D to a F. Teva Pharmaceutical Industries Limited Sponsored ADR is engaged in the provision of pharmaceutical services. For more information, get Portfolio Grader’s complete analysis of TEVA stock.

Novo Nordisk A/S Sponsored ADR Class B (NVO) is having a tough week. The company’s rating falls from a C to a D. Novo Nordisk A/S Sponsored ADR Class B develops, produces, and markets pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of NVO stock.

Slipping from a D to a F rating, Dr. Reddy’s Laboratories Ltd. Sponsored ADR (RDY) takes a hit this week. Dr. Reddy’s Laboratories Ltd. Sponsored ADR is a global company that produces and markets active pharmaceutical ingredients, intermediates, finished dosage forms, and biologic products. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of RDY stock.

This week, Sanofi Sponsored ADR (SNY) drops from a D to a F rating. Sanofi Sponsored ADR is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The company also gets F’s in sales growth. For more information, get Portfolio Grader’s complete analysis of SNY stock.

Impax Laboratories, Inc. (IPXL) slips from a D to a F this week. Impax Laboratories, Inc. develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The company also gets F’s in earnings surprise and earnings momentum. For more information, get Portfolio Grader’s complete analysis of IPXL stock.

NeuroDerm Ltd. (NDRM) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NDRM stock.

Egalet Corporation (EGLT) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EGLT stock.

This is a rough week for Agile Therapeutics, Inc. (AGRX). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGRX stock.

This week, KemPharm, Inc.’s (KMPH) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of KMPH stock.

Cardiome Pharma Corp. (CRME) experiences a ratings drop this week, going from last week’s D to a F. Cardiome Pharma Corp. focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRME stock.

Endocyte, Inc.’s (ECYT) rating weakens this week, dropping to a F versus last week’s D. Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ECYT stock.

Ritter Pharmaceuticals, Inc. (RTTR) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RTTR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/08/12-pharmaceuticals-stocks-to-sell-now-3/.

©2019 InvestorPlace Media, LLC